Lethe

Drospirenone/Ethinylestradiol, the active ingredient in Lethe, is a combined oral contraceptive presented as a tablet for oral use. It prevents pregnancy in women of reproductive age.

GNH USA supplies Lethe as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lethe is a combined oral contraceptive that acts on the hormonal regulation of the menstrual cycle to prevent pregnancy. - Contraception: prevents unintended pregnancy in women of child‑bearing potential. - Menstrual cycle regulation: helps achieve more predictable bleeding patterns. - Management of androgenic symptoms: may improve acne and hirsutism associated with hormonal imbalance.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: tension‑type or migraine‑like. - Breast tenderness: transient swelling or discomfort. - Weight gain: modest increase in body weight. - Mood changes: irritability or emotional lability. - Spotting or breakthrough bleeding: irregular vaginal bleeding.

Serious or Rare Side Effects: - Venous thromboembolism: deep‑vein thrombosis or pulmonary embolism. - Stroke: ischemic or haemorrhagic events. - Myocardial infarction: heart attack risk. - Severe hypertension: marked increase in blood pressure. - Liver disorders: cholestatic jaundice or hepatic dysfunction. - Allergic reactions: anaphylaxis or severe skin rash.

Before prescribing Lethe, clinicians should evaluate individual risk factors and counsel patients on safe use. - Thrombotic risk assessment: avoid in women with a history of clotting disorders. - Smoking restriction: do not use in smokers over 35 years of age. - Hepatic function review: contraindicated in severe liver disease. - Blood pressure monitoring: may elevate systolic/diastolic readings. - Missed dose guidance: follow specific instructions for skipped tablets. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Lethe may interact with several medicines that alter its effectiveness or safety profile. Major Interactions (Avoid): - Enzyme inducers (rifampin, carbamazepine, phenytoin): reduce contraceptive efficacy. - Antiretrovirals (efavirenz, nevirapine): lower hormone levels. - St. John’s wort: diminishes contraceptive effect. - Certain antibiotics (griseofulvin): may decrease hormone concentrations. - Anticoagulants (warfarin): unpredictable effect on coagulation. Moderate Interactions (Monitor Closely): - Antifungals (ketoconazole, itraconazole): increase hormone exposure. - SSRIs (fluoxetine, sertraline): may raise bleeding risk. - Diuretics (spironolactone): additive potassium‑sparing effect. - NSAIDs (ibuprofen, naproxen): possible blood pressure elevation. - Herbal supplements (ginseng): potential reduction in contraceptive reliability.